BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37269828)

  • 1. Discovery and characterization of cyclic peptides selective for the C-terminal bromodomains of BET family proteins.
    Franck C; Patel K; Walport LJ; Christie M; Norman A; Passioura T; Suga H; Payne RJ; Mackay JP
    Structure; 2023 Aug; 31(8):912-923.e4. PubMed ID: 37269828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic peptides can engage a single binding pocket through highly divergent modes.
    Patel K; Walport LJ; Walshe JL; Solomon PD; Low JKK; Tran DH; Mouradian KS; Silva APG; Wilkinson-White L; Norman A; Franck C; Matthews JM; Guss JM; Payne RJ; Passioura T; Suga H; Mackay JP
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26728-26738. PubMed ID: 33046654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.
    Werner MT; Wang H; Hamagami N; Hsu SC; Yano JA; Stonestrom AJ; Behera V; Zong Y; Mackay JP; Blobel GA
    J Biol Chem; 2020 Feb; 295(7):1898-1914. PubMed ID: 31792058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
    Olp MD; Zhu N; Smith BC
    Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA display reveals a class of high-affinity bromodomain-binding motifs that are not found in the human proteome.
    Low JKK; Patel K; Jones N; Solomon P; Norman A; Maxwell JWC; Pachl P; Matthews JM; Payne RJ; Passioura T; Suga H; Walport LJ; Mackay JP
    J Biol Chem; 2023 Dec; 299(12):105482. PubMed ID: 37992806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET-Family Bromodomains Can Recognize Diacetylated Sequences from Transcription Factors Using a Conserved Mechanism.
    Patel K; Solomon PD; Walshe JL; Ford DJ; Wilkinson-White L; Payne RJ; Low JKK; Mackay JP
    Biochemistry; 2021 Mar; 60(9):648-662. PubMed ID: 33620209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
    Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
    J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bromodomains of BET family proteins can recognize diacetylated histone H2A.Z.
    Patel K; Solomon PD; Walshe JL; Low JKK; Mackay JP
    Protein Sci; 2021 Feb; 30(2):464-476. PubMed ID: 33247496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physachenolide C is a Potent, Selective BET Inhibitor.
    Zerio CJ; Sivinski J; Wijeratne EMK; Xu YM; Ngo DT; Ambrose AJ; Villa-Celis L; Ghadirian N; Clarkson MW; Zhang DD; Horton NC; Gunatilaka AAL; Fromme R; Chapman E
    J Med Chem; 2023 Jan; 66(1):913-933. PubMed ID: 36577036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural investigation of a pyrano-1,3-oxazine derivative and the phenanthridinone core moiety against BRD2 bromodomains.
    Arole AH; Deshmukh P; Sridhar A; Padmanabhan B
    Acta Crystallogr F Struct Biol Commun; 2022 Mar; 78(Pt 3):119-127. PubMed ID: 35234137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and selective bivalent inhibitors of BET bromodomains.
    Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
    Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.
    Wai DCC; Szyszka TN; Campbell AE; Kwong C; Wilkinson-White LE; Silva APG; Low JKK; Kwan AH; Gamsjaeger R; Chalmers JD; Patrick WM; Lu B; Vakoc CR; Blobel GA; Mackay JP
    J Biol Chem; 2018 May; 293(19):7160-7175. PubMed ID: 29567837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromodomain Interactions with Acetylated Histone 4 Peptides in the BRD4 Tandem Domain: Effects on Domain Dynamics and Internal Flexibility.
    Wernersson S; Bobby R; Flavell L; Milbradt AG; Holdgate GA; Embrey KJ; Akke M
    Biochemistry; 2022 Nov; 61(21):2303-2318. PubMed ID: 36215732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain.
    Bai P; Yan L; Bagdasarian FA; Wilks MQ; Wey HY; Wang C
    Chem Commun (Camb); 2022 Aug; 58(69):9654-9657. PubMed ID: 35943085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic analysis of the BET family in adrenocortical carcinoma: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y; Liang Q; Zeng Z; Chen J; Shao Z; Xu Q; Lu X; Cui Y; Zhang J; Lu L; Deng L
    Front Endocrinol (Lausanne); 2023; 14():1089531. PubMed ID: 36793283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.